Not much new from the earlier conference. Some brief points (all 191 related): 1-Dr. Porter made a passing remark that could be taken that 191 BID dosing went well (something to the effect of better dosing then other PI's) 2-4th cohort may be done based on safety/tolerability. 3-Q2 still plan for starting combination trial 4-On track to release data from first 3 cohorts around end of quarter 5-Said Roche can and will design studies with all combinations of anti-virals in their portfolio. Hinted at doing this particular in the true non-responders.
Market Data 
Markets 
AI
